MUMBAI, India and BURLINGAME, California, September 8 /PRNewswire/ --

- Member of the $62.5 Billion Tata Group Invests $11.5 Million in Award-Winning CDN Company

Tata Communications, a leading provider of a new world of communications, and BitGravity, Inc., a next-generation Content Delivery Network (CDN) for interactive broadcasting, announced today the worldwide launch of Tata Communications' CDN service powered by BitGravity. With more than 300 points of presence worldwide, Tata Communications now offers the first truly global CDN service on a state of the art, single ASN global IP network throughout Europe, Asia, North America and India.

PARIS, September 8 /PRNewswire/ --

- The THIN, ROLE and LIVE-DE Studies Used Medical Databases or Medical Records to Compare the Benefits of Different Insulin Treatments in Thousands of People Living With Type 2 Diabetes

- Abstracts 1000, 1001 and 1004

Sanofi-aventis, a world leader in diabetes care, announced the results of three non-interventional studies presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) in Rome, Italy (September 7 - 11, 2008), which demonstrated that treatment with LANTUS(R) (insulin glargine (rDNA origin) injection):

SAN DIEGO, California, September 8 /PRNewswire/ -- G.ho.st (the Global Hosted Operating SysTem pronounced "ghost"),which offers its Web-based G.ho.st Virtual Computer (VC) free of charge to every human being, today launched its brand new G.ho.st Mobile service at the prestigious DEMOfall conference in San Diego. The DEMO conferences are famous as launch pads for some of the world's hottest new technologies.

HIGH WYCOMBE, England, September 8 /PRNewswire/ --

- VELCADE Approved Across all Disease Stages for Broad Spectrum of Patients

Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced the European Commission's approval of VELCADE in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma (MM) who are not eligible for high-dose chemotherapy with bone marrow transplant.

In more than 87 countries worldwide, VELCADE monotherapy had already been approved for the treatment of relapsed and / or refractory MM in patients who have received at least one prior therapy.

LAS VEGAS, September 8 /PRNewswire/ --

- Four New Models Feature the Industry's First Wi-Fi Pager and Industry-Specific Functionalities

Ekahau Inc., a leading provider of Wi-Fi-based Real Time Location Systems (RTLS), at RFID World today introduced four new Wi-Fi tags that expand the functionality of its real-time location tracking solutions. The tags, which were designed in response to customer demand in a number of vertical markets, include a personnel badge tag that offers the industry's first two-way Wi-Fi pager capabilities and other solutions for industrial, retail and temperature sensitive environments.

LONDON, September 8 /PRNewswire/ --

- Acquisition Marks the Launch of a Uniquely Commercial Pioneer in Tidal Current Electricity Generation